BioSpace News Archive

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, provided a business update and reported its financial results for the quarter ended June 30, 2021.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced results from the Company’s Phase 2b trial titled: A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B Infusion in Patients With Aging Frailty.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2021.

Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer will participate in a fireside chat at the Citi 16th Annual Biopharma Conference.

ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results and business updates for the second quarter ended June 30, 2021.

Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended June 30, 2021 .

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time.

Plus Therapeutics, Inc. today announced it will present data on Rhenium-186 NanoLiposome ( 186 RNL) from its Phase 1 ReSPECT™ clinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually Aug 21-25, 2021.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business.